TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06374927

Intervention type: DEVICE
Intervention: Rehabilitation Gaming System (VR-based mobile application)
Description: The study intervention includes using the mobile phone technology RGSapp. This application integrates sensor data for delivering patient-tailored VR and AR-based training via gamified exercises for cognitive training.
Study: NCT05656183

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TruGenome Cardiovascular Disease test
Description: The TruGenome Cardiovascular Disease (CVD) test which consists of an in-silico 200 gene cardiovascular disease panel, a further 4 genes with cardiovascular disease risk alleles, 10 pharmacogenomic genes, 35 non-cardiovascular ACMG secondary finding genes and a polygenic risk score (PRS) for coronary artery disease (CAD) will be utilized in this study.
Study: NCT06282445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 1200mg, administered every 3 Weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2, ivgtt, d1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, po, bid, d1-14, Q3W Maintenance therapy: 1250mg/m2, po, bid, d1-14, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5mg/kg，ivgtt, d1, Q3W
Study: NCT04971070

Intervention type: OTHER
Intervention: Observation and follow-up
Description: Observation and follow-up study
Study: NCT05850819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal silver gelatin sponge
Description: Augment the extraction socket with Gelatamp

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile gauze pack
Description: Extraction socket allowed to heal without augmentation with any material
Study: NCT04741113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An online 15-minute educational module
Description: An online 15-minute educational module with four sections: a) Knowledge about obesity; b) Weight bias definition and impact; c) Strategies to reduce weight bias; d) A short quiz.~The module will be based on relevant literature and expert opinion
Study: NCT05043272

Intervention type: BIOLOGICAL
Intervention: SARS-COV-2 VACCINE
Description: The antibody titer and adverse reactions were observed.

Intervention type: BIOLOGICAL
Intervention: SARS-COV-2 VACCINE
Description: The antibody titer and adverse reactions were observed.

Intervention type: BIOLOGICAL
Intervention: SARS-COV-2 VACCINE
Description: The antibody titer and adverse reactions were observed.
Study: NCT05178459

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropathy measurement
Description: Patient will step on Withings WBS08 and on the Sudoscan to get their sudomotor dysfunction caused by the neuropathy evaluated.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropathy measurement
Description: Patient will step on Withings WBS08 and on the Sudoscan to get their sudomotor dysfunction caused by the neuropathy evaluated.
Study: NCT06058767

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Otoacoustic Emissions Testing
Description: An OAE (Otoacoustic Emissions) test is a non-invasive, quick, and commonly used hearing screening method. It is a non-behavioral test to access the function of the cochlea, which is the inner ear's sensory organ responsible for detecting sound.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Otoacoustic Emissions Testing
Description: An OAE (Otoacoustic Emissions) test is a non-invasive, quick, and commonly used hearing screening method. It is a non-behavioral test to access the function of the cochlea, which is the inner ear's sensory organ responsible for detecting sound.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pure Tone Audiometry
Description: The PTA testing is a hearing screening method used to assess an individual's ability to hear pure tones at different frequencies and at different sound levels. It is a behavioral test in which a child is conditioned to perform a play-based task upon hearing sounds at multiple frequencies.
Study: NCT06407453

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: There will be no interference ergonomics training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: upper extremity strengthening exercises upper extremity stretching exercises ergonomics training posture training relaxation exercises
Study: NCT06227533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic regeneration using concentrated growth factor compared with Platelet rich fibrin
Description: regeneration of mature necrotic teeth with periapical abscess using concentrated growth factor compared with Platelet rich fibrin to allow healing of periapical lesion and regaining sensibility

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic regeneration using concentrated growth factor compared with Platelet rich fibrin
Description: regeneration of mature necrotic teeth with periapical abscess using concentrated growth factor compared with Platelet rich fibrin to allow healing of periapical lesion and regaining sensibility
Study: NCT05061732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: 0.5g qid
Study: NCT05713175

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVA plantar orthosis
Description: Treatment consisting of a personalized plantar orthosis fabricated in 45º shore A hardness Ethyl Vinyl Acetate (EVA), which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.
Study: NCT05756023

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the pregnancy rate at IVF / ICSI cycles
Description: To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the pregnancy rate at IVF / ICSI cycles
Description: To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS
Study: NCT05350215

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo pills for a week, 1 pill 4 hr before sleep and 1 pill 30 min before sleep

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine Oral Capsule [Strattera]
Description: Atomoxetine for a week: 40 mg for 3 days 30 min before sleep, 80 mg for 4 days 30 min before sleep Simultaneous administration of DAW2020 for a week, 34 mg 4 h before sleep
Study: NCT05713175

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVA plantar orthosis
Description: Treatment consisting of a personalized plantar orthosis fabricated in 45º shore A hardness Ethyl Vinyl Acetate (EVA), which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polypropylene plantar orthosis
Description: Treatment consisting of a personalized plantar orthosis fabricated in 4mm polypropylene, which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.Orthosis fabricated following the inverted orthotic technique.
Study: NCT04789720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Monitoring & Systematic Assessment and Reporting System in Young Survivors (SyMon-SAYS)
Description: Participants will complete a 9-item SyMon-SAYS symptom assessment checklist every week during the intervention phase (Intervention Group: weeks 1-16; Waitlist Control: weeks 9-16) through Epic MyChart via mobile app, computer or tablet. Patients' symptom scores will be monitored and reported to their oncology care providers. When a patient symptom score trigger threshold is met, the system will generate an email alert through Epic (electronic medical record system) messaging to the provider. The provider will take appropriate actions using his/her clinical judgement, including contacting patients and families when needed. Symptom scores overtime will be available in MyChart (patient-facing component of the Epic electronic medical record system) for patients and parents to review and to discuss with the child's provider during clinical visits.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Symptom Monitoring & Systematic Assessment and Reporting System in Young Survivors (SyMon-SAYS)
Description: Participants will complete a 9-item SyMon-SAYS symptom assessment checklist every week during the intervention phase (Intervention Group: weeks 1-16; Waitlist Control: weeks 9-16) through Epic MyChart via mobile app, computer or tablet. Patients' symptom scores will be monitored and reported to their oncology care providers. When a patient symptom score trigger threshold is met, the system will generate an email alert through Epic (electronic medical record system) messaging to the provider. The provider will take appropriate actions using his/her clinical judgement, including contacting patients and families when needed. Symptom scores overtime will be available in MyChart (patient-facing component of the Epic electronic medical record system) for patients and parents to review and to discuss with the child's provider during clinical visits.
Study: NCT04833946

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Andrographis paniculata [150 mg]
Description: One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose (MCC)
Description: One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
Study: NCT05870969

Intervention type: BEHAVIORAL
Intervention: Liver cancer surveillance every 3 months
Description: Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam

Intervention type: BEHAVIORAL
Intervention: Liver cancer surveillance every 3 months
Description: Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam

Intervention type: BEHAVIORAL
Intervention: Liver cancer surveillance every 6 months
Description: Follow up every 6 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam

Intervention type: BEHAVIORAL
Intervention: Liver cancer surveillance annually
Description: Follow up annually for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
Study: NCT04783311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuCorVac-19
Description: Two intramuscular doses (0.5mL per dose) at 3-week interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuCorVac-19
Description: Two intramuscular doses (0.5mL per dose) at 3-week interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuCorVac-19
Description: Two intramuscular doses (0.5mL per dose) at 3-week interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuCorVac-19
Description: Two intramuscular doses (0.5mL per dose) at 3-week interval

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Two intramuscular doses (0.5mL per dose) at 3-week interval

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Two intramuscular doses (0.5mL per dose) at 3-week interval

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Two intramuscular doses (0.5mL per dose) at 3-week interval
Study: NCT05713175

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polypropylene plantar orthosis
Description: Treatment consisting of a personalized plantar orthosis fabricated in 4mm polypropylene, which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.Orthosis fabricated following the inverted orthotic technique.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixtoe device
Description: Fixtoe Device, simulating the metatarsophalangeal stabilization tape technique is worn for one month, prior to definitive treatment consisting of a personalized plantar orthosis.
Study: NCT06471959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin in the study comes in the form of the study drug, PYEX. PYEX is a drug substance which is a partially purified fraction of the extract of Psilocybe cubensis mushroom fruiting bodies. It is a mixture of indole alkaloids, other mushroom fruiting body components and stabilization excipients. The major indole alkaloids present include psilocybin and psilocin (dephosphorylated psilocybin). PEX010 is a capsule for oral administration and is manufactured with PYEX (12.5-14.0% psilocybin), excipients, and HPMC (hydroxypropyl methyl cellulose) capsules.
Study: NCT06058767

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pure Tone Audiometry
Description: The PTA testing is a hearing screening method used to assess an individual's ability to hear pure tones at different frequencies and at different sound levels. It is a behavioral test in which a child is conditioned to perform a play-based task upon hearing sounds at multiple frequencies.
Study: NCT05703724

Intervention type: DEVICE
Group type: OTHER
Intervention: AI algorithm for the detection of glaucoma
Description: The investigational device that will be used during this study is an AI algorithm embedded into an API for the detection of glaucoma developed by MONA.health
Study: NCT03749928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OstiSense biosensor - active
Description: The activated biofeedback back night guard will be used to reduce sleep bruxism

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: OstiSensor biosensor - not activated
Description: A not-activated night guard will be used as control device
Study: NCT06521827

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course radiotherapy
Description: short course palliative radiotherapy
Study: NCT05234918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediatric Rotary File Systems
Description: * Kedo S plus (p1 molar file ) (A1 anterior file)~* Kidzo-file system 25/4 30/4 30/6

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediatric Rotary File Systems
Description: * Kedo S plus (p1 molar file ) (A1 anterior file)~* Kidzo-file system 25/4 30/4 30/6

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediatric Rotary File Systems
Description: * Kedo S plus (p1 molar file ) (A1 anterior file)~* Kidzo-file system 25/4 30/4 30/6
Study: NCT05708573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: In Treatment Period 1, participants will receive a single oral tablet of rosuvastatin in the morning of Day 1. In treatment period 2, on the morning of Day 4, participants will receive a single 20 mg dose of rosuvastatin (co-administered with the morning dose of ALXN2040).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2040
Description: In Treatment Period 2, participants will receive oral tablets of ALXN2040 three times daily on Days 1 through 7.
Study: NCT04966624

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LUVS ventilatory strategy composed of a bundle of measures
Description: Ventilation in APRV mode early prone sessions, adjustment of positive expiratory pressure according to the patient's BMI and no curarization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)
Description: Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)
Study: NCT05232214

Intervention type: DEVICE
Intervention: Biometry
Description: Only one eye from each patient will be included in the study. All patients included in the study will undergo biometric measurements in a random fashion with the three devices (IOLMaster 700, Argos and Anterion Heildelberg). Each patient will be measured three times with each device
Study: NCT05045196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promoting conversations
Description: The Health-promoting conversations intervention is a conversation model between the patient, family members, and a trained nurse. Patients and families included in the study will, after submitting base-line-data, be randomized to
Study: NCT06367660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Bupivacaine-Fentanyl and Bupivacaine-Dexmedetomidine
Description: In patients undergoing elective LSCS under subarachnoid block, group BF will receive 0.5% hyperbaric bupivacaine 10mg (2ml) with fentanyl 10 mcg (0.2ml) with total of 2.2 ml and group BD will receive 0.5% hyperbaric bupivacaine 10 mg with Dexmedetomidine 5mcg (0.2ml) total volume 2.2ml. Assessment of intraoperative visceral pain will be done by self-reporting of patients, who are previously educated, as poorly localized discomfort or dragging, pulling heaviness or unpleasant feeling or pain with or without nausea and will be categorized according to preformed scale.
Study: NCT04091594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible orthotic
Description: Participants will receive the SIAFO to wear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard orthotic
Description: Participants will received the standard AFO to wear
Study: NCT06554600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160mg bid PO（d0-d20）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin on Day 2 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 70 mg/m2 Bendamustine on Days 2 and 3 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab on Day 1 of each cycle.
Study: NCT05478785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin micelle injection (HA132)
Description: HA132 will be administered intravenously (IV), once per 3 weeks.
Study: NCT05334472

Intervention type: OTHER
Intervention: Kesimpta
Description: There was no treatment allocation. Patients administered Kesimpta by prescription that started before inclusion of the patient into the study were enrolled.
Study: NCT05265858

Intervention type: PROCEDURE
Intervention: Total Hip Arthroplasty
Description: Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA)
Study: NCT04633369

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary fibers
Description: during days 13-22 the participants will consume the dietary fiber according to their randomization and continue fasting. Participants will be asked to collect stool and oral samples 4 times during this period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary fibers
Description: during days 13-22 the participants will consume the dietary fiber according to their randomization and continue fasting. Participants will be asked to collect stool and oral samples 4 times during this period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary fibers
Description: during days 13-22 the participants will consume the dietary fiber according to their randomization and continue fasting. Participants will be asked to collect stool and oral samples 4 times during this period.
Study: NCT06388135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab Combined With Nab-paclitaxel and Cisplatin
Description: Serplulimab (200 mg), cisplatin (60-75 mg/m2), and nab-paclitaxel (135 mg/m2) administered intravenously at the beginning of every 3-week cycle.
Study: NCT06513923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: In Remimazolam group, the induction dose of remimazolam is 0.3 mg/kg based on previous studies, the maintenance of anesthesia is 0.3-0.7 mg/kg/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: In Remimazolam group, the induction dose of remimazolam is 0.3 mg/kg based on previous studies, the maintenance of anesthesia is 0.3-0.7 mg/kg/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: Immediately after the cessation of remimazolam infusion in PACU(PACU, Postanesthesia care unit), the nurses who are blind to the anesthesia management were asked to administer the flumazenil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: For propofol group, the induction of propofol is 1.5-2.0 mg/kg, followed by the maintenance of propofol infusion with 6-8 mg/kg/hr throughout the surgical procedure.
Study: NCT01882712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 Gel 0.5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD07805/47 Gel Placebo
Study: NCT06123273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-oriented training
Description: IG received an exercise-oriented training with a 20-minute presentation including graphics, in line with clinical guidelines, in addition to routine recommendations. The training included information about the benefits of exercise and the harms of a sedentary life, the relationship between exercise and chronic diseases, suggestions to have a more active lifestyle and on how to exercise, the duration and form of exercise necessary for a healthy life, and the things to be considered while exercising. During the three-month follow-up, the subjects in the IG were called every two weeks to ask about their weight measurements, their level of exercise, and how much they walked. The subjects' questions, if any, were answered, and the interview was completed by making exercise suggestions.
Study: NCT05677477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation training
Description: A mother scenario with a baby with physiological jaundice will be implemented with the intervention group.
Study: NCT05858476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 21-Day Detox and Green Drink supplement
Description: Detox plan description:~7AM Water 16oz. 8AM Green Drink 16oz. 9AM Ultra Shake 16oz. 9-12PM Water 24 - 48oz. 12PM Green Drink 16oz. 12:30 - 2PM Water 24 - 48oz. 2PM Green Drink 16oz. 3PM Ultra Shake 16oz. 3:30- 6PM Water 24 - 48oz. 6PM Green Drink 16oz. 7PM Detox Soup 16oz. 7:30 - 10PM Water 24 - 48oz. This 21-day period will be followed by 7 days of consuming the Green Drink Supplement.